Biopharma | January 23, 2026
Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
While Merck can appeal, Halozyme said it expects the order to hold
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Subscribe To Our Newsletter & Stay Updated
